Loading clinical trials...
Loading clinical trials...
Evaluation of the Clinical Efficacy and Safety of Luspatercept Combined With Low-dose Thalidomide Versus Luspatercept Alone in the Treatment of Adult Patients With Transfusion-dependent β-thalassemia
Conditions
Interventions
Luspatercept combined with low-dose thalidomide
Luspatercept plus placebo
Locations
8
China
Southern Medical University Shenzhen Hospital
Shenzhen, Guangdong, China
Affiliated Hospital of Youjiang Medical College for Nationalities
Baise City, Guangxi, China
Baise People's Hospital
Baise City, Guangxi, China
Liuzhou People's Hospital
Liuchow, Guangxi, China
Liuzhou Workers' Hospital
Liuchow, Guangxi, China
Yulin First People's Hospital
Yulin, Guangxi, China
Start Date
February 1, 2026
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2027
Last Updated
January 13, 2026
Lead Sponsor
Rongrong Liu
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions